Pneumatocele during sorafenib therapy: first report of an unusual complication

Paloma Sangro; Idoia Bilbao; Nerea Fernández-Ros; Mercedes Iñarrairaegui; Javier Zulueta; JI Bilbao; Bruno Sangro

doi:10.18632/oncotarget.23599

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Case Reports:

Pneumatocele during sorafenib therapy: first report of an unusual complication

Paloma Sangro, Idoia Bilbao, Nerea Fernández-Ros, Mercedes Iñarrairaegui, Javier Zulueta, JI Bilbao and Bruno Sangro _

PDF | HTML | How to cite

Oncotarget. 2018; 9:6652-6656. https://doi.org/10.18632/oncotarget.23599

Metrics: PDF 1987 views | HTML 2502 views | ?

Abstract

Paloma Sangro1, Idoia Bilbao1, Nerea Fernández-Ros1, Mercedes Iñarrairaegui2, Javier Zulueta3, JI Bilbao4 and Bruno Sangro2

1Liver Unit, Department of Internal Medicine, Clínica Universidad de Navarra-IDISNA, Pamplona, Navarra, Spain

2Liver Unit, Department of Internal Medicine, Clínica Universidad de Navarra-IDISNA and CIBEREHD, Pamplona, Navarra, Spain

3Department of Respiratory Diseases, Clínica Universidad de Navarra-IDISNA, Pamplona, Navarra, Spain

4Vascular and Interventional Radiology Unit, Clínica Universidad de Navarra-IDISNA, Pamplona, Navarra, Spain

Correspondence to:

Bruno Sangro, email: [email protected]

Keywords: iung toxicity; STAT3; antiangiogenics; radioembolization; hepatocellular carcinoma

Received: August 18, 2017 Accepted: November 27, 2017 Published: December 22, 2017

ABSTRACT

Sorafenib is a multi-kinase inhibitor and a vascular endothelial growth factor (VEGF) inhibitor approved to treat patients with advanced hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma. Its most common side effects are asthenia/fatigue, skin toxicity, diarrhea and arterial hypertension. Reported respiratory adverse reactions include dyspnea, cough, pleural effusion and hoarseness. The aim of this report is to describe for the first time the occurrence of pneumatocele in two patients treated with Sorafenib. Patients had no respiratory symptoms and alternative diagnoses were ruled out. Primary tumors were different (liver metastases from a pancreatic neuroendocrine tumor and hepatocellular carcinoma) but both patients had been treated with yttrium 90 radioembolization 9 and 17 months before starting on Sorafenib, respectively. No complications occurred and Sorafenib withdrawal was followed by radiologic improvement.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23599

Publication Alerts

Case Reports:

Pneumatocele during sorafenib therapy: first report of an unusual complication

Abstract